AN2 Therapeutics, Inc. (ANTX) carries a dividend yield of 0.0%. As a clinical-stage biopharmaceutical enterprise focused on developing novel treatments for rare and infectious diseases, the company does not distribute dividends. All available financial capital is retained and reinvested directly into research and development, clinical trials, and pipeline expansion efforts rather than being paid out as cash dividends to common shareholders.